irAEs
Chronic Adverse Events of Anti–PD-1 Treatment Common and Lasting
More than 43% of patients receiving an anti–programmed death-1 agent for adjuvant treatment of stage III/IV ...
AUGUST 18, 2021
Immunotherapy Toxicities
Immune checkpoint inhibitors and adoptive cell transfer therapies have unlocked new avenues to treat cancer, but ...
OCTOBER 12, 2020
Load more